Adaptimmune Therapeutics plc (NASDAQ:ADAP) Receives $1.83 Consensus Price Target from Analysts
Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price […]
Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price […]
